Moderna wants to extent its European footprint
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Centauri Therapeutics starting with £24m financing
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics in US$1.7bn deal with MSD
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital launches new NBC III fund
Newton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.
New funds to boost European life sciences
European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
Aicuris licences antisense RNA know-how from Hybridize Therapeutics
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
BioNTech collaborates with AGC Biologics
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Council confirms European Scale-up Initiative
EU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide €10bn for late-state tech companies.
Protix raises €50m for expansion
Dutch insect protein specialist Protix has raised €50m for expansion and development from international investors and the ECBF.
Detect the Omicron variant of SARS-CoV-2 with Meridian Bioscience’s new antibody pair
A rapid antigen test provides a fast and reliable indication of the presence of the SARS-CoV-2 virus, the causative agent of Covid-19. A positive result of an antigen test is reliable, whereas a negative result does not completely rule out infection with the SARS-CoV-2 virus. The success of rapid tests is therefore limited by the sensitivity of the antibodies used.